top of page

Previous Speakers (2024 part 1)

Some seminars were recorded and accessible for a limited time on our youtube channel.


January 11th, 2024

Host: Katherine Donovan

Positive Selection Screening for Natural Product Degraders of Undruggable Targets in Cancer

William G. Kaelin

Dana-Farber Cancer Institute

William Kaelin is the Sidney Farber Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, Senior Physician-Scientist at Brigham and Women's Hospital and Howard Hughes Medical Institute Investigator. Among his many accolades, Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the National Academy of Medicine, the American Society of Clinical Investigation, and the American College of Physicians. Dr. Kaelin’s research seeks to understand how, mechanistically, mutations affecting tumor-suppressor genes cause cancer. His long-term goal is to lay the foundation for new anticancer therapies based on the biochemical functions of such proteins.

Matt Boudreau

Dana-Farber Cancer Institute

Matt completed his Ph.D. at the University of Illinois at Urbana-Champaign under the direction of Prof. Paul Hergenrother, where he worked on a variety of new anticancer approaches. He is currently an NCI K00 postdoctoral fellow in Prof. William G. Kaelin, Jr.’s laboratory. His current work utilizes positive selection screening to find novel natural products that degrade crucial transcription factors found in cancer.


January 25th, 2024

Host: Breanna Zerfas

Ingo Hartung

Merck Healthcare KGaA

Quality criteria for degraders – Probing biology with a novel modality

Ingo Hartung is a synthetic organic chemist by training (PhD University of Hannover/Germany, Postdoc Stanford University/US) with close to 20 years of Pharma industry experience (Schering AG, Bayer AG, Merck KGaA). He has been project leader in oncology and cardiology NCE drug discovery and has had portfolio responsibility for preclinical research in the areas of epigenetics, tumor metabolism and immuno-oncology. He is current the global head of Merck’s Medicinal Chemistry & Drug Design department. In addition to this role, Ingo is leading Merck’s global cross-functional targeted protein degradation platform. His research interests comprise all aspects of innovation in small molecule drug discovery with a special focus on new synthetic modalities like protein degraders. Ingo Hartung is a member of the Steering Committee of the Chemistry in Cancer Research Working Group of the AACR and on the Advisory Board of the President of the European Federation of Medicinal Chemistry.


February 8th, 2024

Host: Zuzanna Kozicka & Mikolaj Slabicki


Amanda Ng


Isogenic CPA: A morphological profiling approach for discovering molecular glues

There is a saying that “A picture is worth a thousand words”. Turns out, you can get a lot of information from pictures of cells as well using morphological profiling. Amanda Ng is a PhD student in the laboratory of Georg Winter at the Center for Molecular Medicine in Vienna, Austria. Her work focuses on adapting a morphological profiling approach called the Cell Painting assay for the discovery of molecular glues. Prior to joining the Winter lab, she pursued her BSc. (Hons) studies majoring in Life Sciences at the National University of Singapore.

High resolution - 202011_UNSWChem_Portraits_PRINT_126.jpg

William A. Donald

University of South Wales

Oligomeric Remodeling by Molecular Glues Revealed Using Native Mass Spectrometry and Mass Photometry

William A. Donald is a Professor and Australian Research Council Future Fellow in the School of Chemistry at the University of New South Wales, Sydney. He completed his Ph.D. at the University of California Berkeley in 2010. After a research fellowship at the University of Melbourne in the Bio21 Institute, he joined the School of Chemistry at the University of New South Wales in 2013. He is currently an associate editor of the Journal of Enzyme Inhibition and Medicinal Chemistry. His research interests include developing mass spectrometry-based methods to investigate protein interactions and post-translational modifications.


February 22nd, 2024

Host: Zuzanna Kozicka

Susan Shao

Harvard Medical School

Mechanism of a small molecule translation inhibitor

Sichen (Susan) Shao, PhD, is an associate professor in the Department of Cell Biology at Harvard Medical School. The Shao lab studies protein biosynthesis and quality control mechanisms using approaches integrating biochemistry, cell biology, and structural biology. The molecular insights into ribosome-associated quality control and membrane protein sorting elucidated by her lab advance our understanding of the emergence and treatments of genetic and neurodegenerative disorders. Her discoveries have been recognized by the NIH New Innovator Award, a Vallee Scholar Award, a Packard Fellowship, and the ASCB Günter Blobel Early Career Award.

Dr. Shao earned her BSE degree in Chemical Engineering from Princeton University and a PhD in Biology from the graduate partnership program between Johns Hopkins University and the National Institutes of Health. She conducted postdoctoral research with Dr. Manu Hegde at the MRC Laboratory of Molecular Biology in the United Kingdom before starting her lab.

bottom of page